Novartis gets approval for Genmab drug against multiple sclerosis in Europe
Genmab's partner Novartis has received European marketing authorization for the drug Kesimpta which treats relapsing multiple sclerosis.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
In January, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) recommended approving the drug Kesimpta with the active agent ofatumumab, and now, this has led to a European marketing authorization from the EU Commission, according to a press statement from Genmab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
